Mark Gallardo, MD
Ophthalmology · Las Cruces, NMNPI 1659302099
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $796,287 of the $1,249,606 with a category attached, or 63.7%. Glaukos Corporation accounts for 80.0% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2022 at $413,416 and has fallen 59.4% since, to $167,915 in 2025. Among ophthalmology clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 592 payments — averaging $2110.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$999K
- AbbVie$60K
- Ellexiscience$52K
- Ivantis, Inc$35K
- Sight Sciences, Inc.$30K
- Nova Eye, Inc.$29K
- plus $45K from 22 others
Across 2,150 payments — averaging $1471.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$986K
- Glaukos Corporation$853K
- AbbVie$709K
- Sight Sciences, Inc.$327K
- Ocular Therapeutix, Inc.$202K
- Ivantis, Inc$87K
What the payments were for
- Royalty or licence$796,28764%
- Consulting fees$308,29225%
- Speaking & faculty fees$89,0127%
- Grants$5,0000%
- Travel & lodging$19,4722%
- Food & beverage$17,4531%
- Education$430%
- Gifts$1450%
- Other$13,9031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 159 | $999,286 |
| AbbVie(2 entities) | 150 | $59,619 |
| Ellexiscience | 3 | $51,749 |
| Ivantis, Inc | 31 | $35,156 |
| Sight Sciences, Inc. | 22 | $29,534 |
| Nova Eye, Inc. | 8 | $29,370 |
| Alcon | 63 | $21,031 |
| Aerie Pharmaceuticals, Inc. | 45 | $13,046 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 16 | $3,059 |
| Bausch & Lomb Americas Inc. | 16 | $2,103 |
| Carl Zeiss Meditec, Inc. | 2 | $2,025 |
| Alcon Research LLC | 2 | $1,778 |
| Novartis | 31 | $316 |
| Carl Zeiss Meditec USA, Inc. | 5 | $302 |
| Lumibird Medical Inc. | 1 | $181 |
| Biotissue Holdings Inc. | 6 | $156 |
| Sun Pharmaceutical Industries Inc. | 4 | $141 |
| NEW World Medical,inc. | 6 | $138 |
| Medtronic | 1 | $121 |
| Ocular Therapeutix, Inc. | 3 | $111 |
| Rxsight Inc | 3 | $87 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $86 |
| Johnson & Johnson | 3 | $57 |
| Tarsus Pharmaceuticals, Inc. | 2 | $41 |
| Kala Pharmaceuticals, Inc. | 2 | $38 |
| Oyster Point Pharma, Inc. | 1 | $27 |
| Harrow Eye, LLC | 1 | $25 |
| Shire North American Group Inc | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iAccess Precision Blade$361,998
- IACCESS$200,272
- iAccess Trabecular Trephine$102,598
- XEN GLAUCOMA TREATMENT SYSTEM$43,539
- Hydrus Microstent$26,143
- iDose$24,815
- Hydrus$24,103
- OMNI$23,109
- iStent inject W$21,885
- iStent inject Trabecular Micro-Bypass Stent System$21,446
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$17,625
- iStent Trabecular Micro-Bypass Stent System$15,681
- Rhopressa$12,483
- Rocklatan$12,483
- XEN$10,385
- OMNI(R) SURGICAL SYSTEM (US)$6,147
- iStent infinite Trabecular Micro-Bypass System Model iS3$5,605
- Travoprost Intraocular Implant - iDose$5,200
- Voyager DSLT$5,000
- DURYSTA$2,988
How this compares
$1,249,606 in reported general payments places this provider in the 95th percentile of 81 ophthalmology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 327 | $198,867 |
| VyzultaLatanoprostene Bunod | 358 | $187,703 |
| XiidraLifitegrast | 118 | $175,404 |
| LumiganBimatoprost | 288 | $163,444 |
| RocklatanNetarsudil Mesylat/Latanoprost | 140 | $118,896 |
| CombiganBrimonidine Tartrate/Timolol | 220 | $96,803 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 470 | $87,760 |
| RestasisCyclosporine | 82 | $84,717 |
| Prednisolone Acetate | 841 | $35,144 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 87 | $30,367 |
| Alphagan PBrimonidine Tartrate | 58 | $29,738 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,485 | $27,841 |
| Brimonidine Tartrate | 935 | $26,868 |
| MoxifloxacinMoxifloxacin Hcl | 592 | $23,150 |
| Latanoprost | 1,947 | $23,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $59,619 | $374,701648 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $2,103 | $363,107476 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $13,046 | $317,762467 claims |
| AlconSimbrinza, Azopt | $21,031 | $36,827101 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $27 | $12,78919 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $3,059 | $3,70226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 81 ophthalmology providers in New Mexico.
Other ophthalmology in Las Cruces
- Charles SchafferLas Cruces$5K
- Edward HernandezLas Cruces$3K
- Robert VillalobosLas Cruces$2K
- Eric WeberLas Cruces$234
- Robert MelendezAlbuquerque$349K
- John PitcherAlbuquerque$307K
- Christopher RoybalAlbuquerque$51K
- Paul GulbasRuidoso$14K
- Stephen ColemanAlbuquerque$12K
- Rachel DavisAlbuquerque$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.